Galecto, INC 8-K filings

Damora Therapeutics, Inc. has successfully completed its redomestication from Delaware to the Cayman Islands, effective July 16, 2026, with ordinary shares to trade under a new CUSIP starting July 20, 2026.

Damora Therapeutics, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of new directors and the ratification of its independent auditor.

Damora Therapeutics announced the departure of its CFO, Lori Firmani, effective May 1, 2026, with Brian Burkavage appointed as the new principal financial and accounting officer.

Damora Therapeutics has dismissed EY Denmark and appointed Ernst & Young LLP as its new independent auditor.

Damora Therapeutics announced the appointment of Jennifer Jarrett as President and CEO, alongside significant changes to its Board of Directors.

Galecto, Inc. announced the closing of a public offering of 16,644,737 common shares at $19.00 per share, raising approximately $295.9 million in net proceeds to fund operations into Phase 3 development of DMR-001.

Galecto, Inc. announced the departure of its CEO, appointed an interim successor, increased authorized common stock, and approved several key proposals at a special stockholder meeting.

Galecto, Inc. announced the acquisition of Damora Therapeutics, adding a potentially best-in-class mutCALR-driven myeloproliferative neoplasm portfolio and securing $285 million in private placement funding, extending its cash runway into 2029.

Galecto, Inc. announced the issuance of a warrant to Paramora Holding LLC for 628,302 shares and the appointment of Sherwin Sattarzadeh as Chief Operating Officer.

Galecto, Inc. filed an amendment to correct a scriveners error in the authorized number of Series C Non-Voting Convertible Preferred Stock shares.

Galecto, Inc. completed the acquisition of Damora Therapeutics, Inc. and secured an oversubscribed $285 million private placement to advance a portfolio of anti-mutant calreticulin (mutCALR) targeted therapies for Myeloproliferative Neoplasms.

Galecto, Inc. announced that all proposals, including director elections, preferred stock conversion, and auditor ratification, were approved by stockholders at its Annual Meeting on June 18, 2025.

Galecto, a clinical-stage biotech company, has appointed Dr. Amy Wechsler to its Board of Directors, bringing her extensive experience in healthcare and strategic leadership.

Galecto, a clinical-stage biotech company, has refocused its pipeline on oncology and liver disease, acquiring global rights to a novel AML treatment while leveraging its existing clinical-stage asset.

Galecto, Inc. has regained compliance with Nasdaq's minimum bid price requirement after its stock price closed at or above $1.00 per share for a sustained period.

Galecto Inc. has completed a 1-for-25 reverse stock split, reducing the number of outstanding shares to 1,248,266.

Galecto Inc. has completed a 1-for-25 reverse stock split, effective August 29, 2024, to maintain Nasdaq listing compliance.

Galecto, Inc. held its annual meeting on June 20, 2024, where stockholders approved the election of a new director, a reverse stock split, and the ratification of the company's accounting firm.

Galecto Inc. has been granted an extension until September 22, 2024, to regain compliance with Nasdaq's minimum bid price requirement after transferring to the Nasdaq Capital Market.